{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"A DLT (dose limiting toxicity) is defined as a therapy-related grade III or IV Bearman (transplant) toxicity within 30 days of transplant.","groups":[{"description":"Patients receive indium-111 anti-CD45 monoclonal antibody BC8 IV on day -28 and (if necessary) day -21. Patients receive yttrium-90 anti-CD45 monoclonal antibody BC8 IV on day -28, -14, and -13. Patients then undergo autologous peripheral blood stem cell transplantation on day 0.\n\nindium In 111 anti-CD45 monoclonal antibody BC8: Given IV\n\nyttrium Y 90 anti-CD45 monoclonal antibody BC8: Given IV\n\nperipheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell transplant","id":"OG000","title":"Treatment (Yttrium-90 Anti-CD45 Monoclonal Antibody BC8)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days after receiving study drug","title":"Percentage of Participants With Dose Limiting Toxicities (DLT) of Yttrium-90 Anti-CD45","type":"PRIMARY","unitOfMeasure":"Participants"}